



Krishna Educational Institutions Chairman S. Malarvizhi, Managing Trustee Adhitya donates Rs. 1 crore to Chief Minister M.K. Stalin towards Chief Minister's Covid Relief fund.



Dr. MGR Education and Research Institution Chairman A.C.S. Arunkumar donates Rs. 50 lakhs.



Poorvika Mobiles proprietor Yuvaraj donates Rs. 50 lakhs

2nd Covishield jab after 12 to 16 weeks; Centre nod for expert view

New Delhi, May 14: The Centre on Thursday approved extending the gap between the two doses of the Covishield vaccine to 12-16 weeks following a recommendation from a government panel, and said it is a "science-based decision" taken with confidence that there will be no extra risk.

However, the National Technical Advisory Group on Immunisation (NTAGI) has suggested no change for the dosage interval for Covaxin, the Union health ministry said.

"Based on the available real-life evidences, particularly from the UK, the COVID-19 Working Group agreed for increasing the dosing interval to 12-16 weeks between two doses of Covishield vaccine. No change in interval of Covaxin vaccine doses was recommended," the ministry said.

The present gap between two doses of Covishield, manufactured by the Serum Institute of India, is 6-8 weeks.

The Hyderabad-based Bharat Biotech's indigenously developed

Move to ease vaccine shortage

PM to interact with magistrates in hit dists

Prime Minister Narendra Modi will interact with district magistrates of 100 districts with high caseloads of COVID-19 infections in two meetings on May 18 and 20, government sources said on Thursday.

While DMs of 46 districts from nine states will be part of the first meeting, those from 54 districts from 10 states will attend the second meeting, they said, adding that respective chief ministers will be present in these interactions.

This will be the first such interaction that the prime minister will have with top district-level administrative officers on the COVID-19 situation.

So far, he has held a number of meetings with chief ministers from across the country and also, in some cases, from high caseload states on the pandemic situation since its first outbreak in 2020.

According to the latest data from the Union Health Ministry, just ten states account for over 72 per cent of new COVID-19 cases reported in a span of 24 hours and these include Maharashtra, Delhi, Haryana, Uttar Pradesh, Kerala, Karnataka, Tamil Nadu, Andhra Pradesh, West Bengal and Rajasthan.

Also, just ten states account for 74.30 per cent of the new deaths.

Covaxin and Oxford-AstraZeneca's Covishield, being manufactured by the Pune-based SII, are currently being used in India's inoculation drive against coronavirus.

The Central government's move comes amid reports from several states about shortage of COVID-19 vaccines. Some states and UTs have also reported that

they had to suspend its vaccination drive for 18-44 years in view of the scarcity. While Maharashtra decided on Wednesday to suspend its drive to vaccinate people in the age group of 18 to 44 years in view of vaccine shortage, Delhi also temporarily shut Covaxin-administering centres for this age group as it has run out of stock.

Several states and UTs including Delhi, Maharashtra, Karnataka and Telangana have also decided to opt for global tenders for procurement of anti-coronavirus shots with the domestic supply falling short to meet the rising demand.

Asserting that it has been a "science-based decision" taken based on the recommendations

of the NTAGI, V.K. Paul, member (Health) NITI Aayog said as per studies, initially the dosage interval between two doses of covishield was 4 to 6 weeks but then as more data became available secondary analysis showed increasing the dosage interval to 4 to 8 weeks can have some "advantage". "So in good faith, based on science, without any pressures, they increased the dosage interval to 4 to 8 weeks. Now based on the available real-life evidences, particularly from the UK, the decision to extend it from 6-8 weeks to 12-16 weeks has been taken with confidence that there will not be an extra risk" he said. "This is a dynamic decision and, part of periodic review," Paul added.

Asked if the efficacy of the vaccine will be affected with this extension, Paul said, "The efficacy is so good even after the single dose... it's not a problem at all."

Envoy hails Indian-Americans for aid in COVID fight

Washington, May 14: Indian-Americans have been a pillar of support for India in its fight against COVID-19, Ambassador Taranjit Singh Sandhu said here.

Sandhu, India's Ambassador to the US, held a virtual interaction with some of the prominent Indian-American leaders from across the country on Thursday, during which he appreciated their overwhelming support.

Interacted with Indian American community leaders across the US this afternoon. Diaspora in the US has been a strong pillar of support in our fight against the pandemic. Appreciate their efforts, Sandhu said in a tweet later.

The outpour of assistance demonstrates the strength of the India-US partnership, he noted, and briefed the representatives about India's immediate requirements in the fight against the pandemic.

The Ambassador assured that

the embassy and the consulates remain fully committed in facilitating and channelising the community's offers of assistance.

Several leaders of the community spoke during the interaction, outlining their efforts to contribute to the ongoing efforts in all possible manner.

Indian-American organisations have raised millions of dollars for COVID-19 assistance to India the American India Foundation has raised USD25 million, Sewa International USA \$ 17 million and Indiaspora \$ 2.5 million, among others.

The Dallas-based US India Chamber of Commerce on Thursday shipped 115 ventilators and 800 oxygen concentrators. It has so far raised \$ 1.2 million.

"The situation in India is catastrophic, however, India and the people of India are resilient and will see better days with the support of all of us," the chamber's

founding president, Ashok Mago, said at the virtual meeting with Sandhu.

Tennessee-based eminent Indian-American cardiologist Dr. Indranil Basu Rau has helped send 250 co-ventilators to India. The next batch of 660 more such ventilators is getting ready to be shipped, he said.

Sewa International has spent more than \$ 6 million in the last 15 days to procure lifesaving equipment such as oxygen concentrators, ventilators, BiPap, and CPAP machines as part of its 'Help India Defeat COVID-19' campaign.

"We got a phenomenal response from all Americans to our 'Help India Defeat COVID-19' campaign'. Many corporations, hospitals, and community organisations are calling us to offer help. Sewa volunteers are working hard to connect the dots," Sewa International president Arun Kankani said.

Foreign medical aid pours as India battles big surge

New Delhi, May 14: Germany, Japan, South Korea, Finland and Greece on Thursday delivered to India a large number of medical supplies as the second wave of the coronavirus pandemic continued to ravage various parts of the country.

Two aircraft carrying 100 oxygen concentrators arrived from Japan while South Korea sent 10,000 rapid testing kits, officials said. A consignment of 30 oxygen concentrators, two ventilators and other medical equipment came from Italy.

A shipment from Greece contained 10 portable oxygen cylinders while Germany sent 176 ventilators and 180 trolleys, the officials said.

Another European nation, Finland delivered to India 324 oxygen-filled cylinders and 225 Oximeters. A British company also sent to India 1,200 oxygen cylinders.

"Cooperation with Japan continues. 2 aircrafts carrying a total consignment of 100 oxygen concentrators arrive from Japan. 4 aircrafts in 2 days from Japan have delivered a cumulative of 200 oxygen concentrators. Appreciate this continuing support from our partner," External Affairs Ministry Spokesperson Arindam Bagchi tweeted. He also mentioned the supplies sent by South Korea. "Our continuing cooperation with Republic of Korea. Welcome the shipment of 10000 rapid testing kits from Republic of Korea that arrived today," he said in another tweet.

Stalin writes to PM for zero GST on COVID-19 vaccines

Chennai, May 14: Chief Minister M K Stalin on Thursday urged Prime Minister Narendra Modi to bring the Goods and Services Tax for COVID-19 vaccines and drugs to zero level.

Pending GST compensation and subsidy on rice should be released immediately and adhoc grants-in-aid must be provided as the Centre has

not shared with states the revenue from additional levies on fuel, he said in a letter to Modi. Also, Stalin wanted the borrowing limit increased by one more per cent from the current three per cent of Gross State Domestic Product. State governments were procuring COVID-19 vaccines and drugs to treat the patients and the

Centre for such supplies should be made zero, he said. At a time when the tax revenue of states have seen a steep decline on account of economic growth taking a hit in view of the pandemic, measures including release of GST compensation should be taken up by the Centre to help the state governments.

THAMBI MODERN SPINNING MILLS LIMITED

CIN: L17111TZ1977PLC000776
Regd Office: Omalur Road, Jagir Ammapalayam, Salem-636 302
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2021 (RS. IN LAKHS)

S. No.	Particulars	3 months ended	3 months ended	3 months ended	Year ended	Year ended
		31.12.2020 (Audited)	31.03.2021 (Audited)	31.03.2020 (Audited)	31.03.2021 (Audited)	31.03.2020 (Audited)
1.	a) Revenue from Operations	118.74	48.04	44.57	166.78	191.25
	b) Other Income	1.18	80.23	-	81.41	1.30
	Total Income	119.92	128.27	44.57	248.19	192.55
2.	Expenses					
	a. Cost of Material Consumed	-	-	-	-	-
	b. Purchase of Stock-In-Trade	-	-	-	-	-
	c. Changes in inventories of Finished Goods, Work-In-Progress and Stock -In-Trade	-	-	-	-	-
	d. Employee benefits expense	30.23	12.77	10.93	43.00	58.05
	e. Finance Costs	113.42	55.63	61.70	169.05	181.71
	f. Depreciation and Amortisation expense	47.45	17.33	17.71	64.78	63.27
	g. Other Expenses	68.61	9.93	5.86	78.54	87.09
	Total Expenses	259.71	95.66	96.20	355.37	390.12
3.	Profit / (Loss) from Ordinary Activities after finance costs but before exceptional items (1-2)	(139.79)	32.61	(51.63)	(107.18)	(197.57)
4.	Exceptional Items	-	-	-	6.96	-
5.	Profit / (Loss) from Ordinary Activities before tax (3-4)	(139.79)	32.61	(51.63)	(114.14)	(197.57)
6.	Tax Expense	-	-	-	-	-
7.	Net Profit / (Loss) from Ordinary Activities after tax	(139.79)	32.61	(51.63)	(114.14)	(197.57)
8.	Other Comprehensive Income					
	i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	iii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
9.	Total Comprehensive Income for the period (7+8)	(139.79)	32.61	(51.63)	(114.14)	(197.57)
10.	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	576.28	576.28	576.28	576.28	576.28
11.	Other Equity excluding Revaluation Reserves as per Balance Sheet	-	-	-	-	-
12.	Earnings Per Share (Face Value of Rs.10/- each) (not annualised) Basic and Diluted	(2.43)	0.57	(0.90)	(1.98)	(3.43)

NOTES:

- The company operates on a single segment namely lease rental income hence no separate disclosure is required.
- The status on investors complaints as on 31.03.2021 Pending at the beginning of the quarter NIL, Resolved during the quarter : NIL Disposed off during the quarter : NIL Lying unresolved: NIL
- Corresponding previous quarter /year figures have been regrouped wherever necessary.
- The above results were approved by the Board of Directors at its meeting held on 12th May 2021.
- Due to COVID-19 our company also face problems like reduction in Revenue, etc...

STATEMENT OF ASSETS AND LIABILITIES

Particulars	31.03.2021	31.03.2020
	ASSETS	
Non-Current Assets		
(a) Property, Plant and Equipment	1 172.19	1 126.56
(b) Capital Work-in-Progress	-	55.20
(c) Other Intangible Assets	0.10	0.58
(d) Financial Assets		
(i) Investments	-	-
(ii) Loans & Advances	9.80	9.35
(iii) Other Non current assets	10.96	10.96
(e) Deferred Tax Asset (Net)	7.62	58.10
Current Assets		
(a) Inventories	-	-
(b) Financial Assets		
(i) Cash and Cash Equivalents	36.62	28.55
(ii) Trade Receivables	246.61	252.69
(iii) Others	49.79	35.54
(c) Current Tax Assets (Net)	30.28	34.70
(d) Other Current Assets	-	-
Total Assets	1 563.97	1 612.23
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share Capital	576.28	576.28
(b) Other Equity	(1 010.26)	(845.64)
LIABILITIES		
Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	1 699.95	1 129.78
(b) Other Non Current Liabilities	138.65	398.70
(c) Provisions	-	-
Current Liabilities		
(a) Financial Liabilities		
(i) Trade Payables	10.56	7.41
(ii) Other Financials Liabilities	148.79	345.70
(b) Other Current Liabilities	-	-
(c) Provisions	-	-
Total Equity and Liabilities	1 563.97	1 612.23

Place: Salem
Date: 12.05.2021

For Thambbi Modern Spinning Mills Limited.,
Managing Director

TN announces incentives for manufacture of medical oxygen, allied instruments

Chennai, May 14: To encourage production of medical oxygen and manufacture of instruments relating to it, the State government announced special package of incentives for companies willing to manufacture medical oxygen in the State.

A high-level meeting chaired by Chief Minister MK Stalin on May 11 which discussed measures to be initiated for attaining self-sufficiency in medical oxygen production.

The meeting decided to encourage the manufacture of medical

oxygen and manufacture of instruments.

The following are The concessions for oxygen production units to be established in Tamil Nadu are The companies that invest in Tamil Nadu to produce oxygen concentrators, oxygen cylinders and medical oxygen will get 30% capital subsidy in two equal instalments.

To avail this concession, concerned units have to commence their production by August 15 this year. The investments made from January 1, 2021 to August 31, 2021 will be

taken into account for extending this concession.

Thirty percent capital subsidy will be allowed for factories which establish plants with a capacity to produce 10 metric tonnes of liquid oxygen per day. The investments made between January 1, 2021 and November 30, 2021 will be taken into account for providing this concession and this capital subsidy will be given in a period of five years. Further for availing this concession, the concerned plant has to commence production before November 30,

2021. Loans will be provided to the above factories immediately with six percent interest subsidy per year through the Tamil Nadu Industrial Investment Corporation. The lands will be allotted to the above factories through SIPCOT/SIDCO on priority basis. The investors will be given clearance through single window system by Tamil Nadu Guidance Bureau TIDCO will encourage joint ventures for producing oxygen concentrators, vaccines, and medical oxygen.

2021. Loans will be provided to the above factories immediately with six percent interest subsidy per year through the Tamil Nadu Industrial Investment Corporation. The lands will be allotted to the above factories through SIPCOT/SIDCO on priority basis. The investors will be given clearance through single window system by Tamil Nadu Guidance Bureau TIDCO will encourage joint ventures for producing oxygen concentrators, vaccines, and medical oxygen.